Abbott Laboratories (ABT) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $97.51. The rating moved from Oversold to Strong Oversold on October 3, 2026.

• Public ratingStrong Oversold (as of October 3, 2026)
• Last close$97.51
• Last changeMoved from Oversold to Strong Oversold on October 3, 2026
• SectorHealthcare
• IndustryMedical Devices

See all oversold Healthcare stocks →

AI analysis

Abbott Laboratories shows a resilient, diversified business mix with strong cash generation and leadership in diagnostics and diabetes monitoring, supported by recurring consumables and disciplined capital allocation. Near-term performance will be shaped by reimbursement dynamics, competitive moves in diabetes therapeutics and device/regulatory execution, while its balance sheet and product pipeline underpin moderate upside over the next month. Market risk-off sentiment and policy-driven pricing pressure represent the principal uncertainties that could compress near-term multiples despite structural strengths.

Key factors

• Diversified portfolio across diagnostics, medical devices, nutrition and established pharmaceuticals providing resilient revenue streams
• Market-leading position in continuous glucose monitoring (FreeStyle Libre) with strong recurring consumables revenue
• Solid balance sheet and cash flow generation supporting dividend, buybacks, R&D and targeted M&A
• Defensive characteristics that attract flows in risk-off environments (healthcare staples, diagnostics)
• Ongoing product innovation and geographic expansion potential in emerging markets and point-of-care diagnostics

Risks

• Policy and reimbursement pressure (Medicare negotiation/IRA implications) that could compress pricing and margins for certain drug/device lines
• Intensifying competition in diabetes care (Dexcom, Roche) and increasing therapeutic competition (GLP-1/adjuvant strategies) that could affect market share or pricing
• Supply-chain disruption or manufacturing issues that could impair device availability and revenue timing
• Regulatory or recall risk for devices and diagnostics which can produce outsized financial and reputational impacts
• Macro risk-off sentiment and soft IPO/healthcare financing windows that can weigh valuation multiples and near-term investor appetite

Latest MarketMoodz coverage

• Midday movers: AMD gains on Bernstein lift; Abbott slides2026-04-16
• Oil Shock Drives March CPI Higher; Markets Brace for Fed Path2026-04-12
• March CPI Seen Jumping 0.9%; Stocks in Focus as Inflation Rises2026-04-09
• GlucoTrack stock rises as data backs FDA filing plans for implantable CGM2026-03-27

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.